Evaluation of Cytogenetic Alterations in Peripheral Blood Lymphocytes of Esophageal Cancer Patients Treated with Radiotherapy or Chemoradiotherapy using Cytokinesis-Blocked Micronucleus Assay
-
Soraya Emamgholizadeh Minaei
,
Hossein Mozdarani
,
Morteza Motazakker
,
Mohsen Mansouri
,
Seyed Mahmoud R. Aghamiri
Abstract
The effects of combined radiotherapy (RT) and chemotherapy in the severity of cytogenetic alterations expressed as micronucleus (MN) in peripheral blood lymphocytes of patients treated for esophageal cancer was evaluated. To do this, blood was obtained from 23 and 15 esophageal cancer patients scheduled for chemo-radiotherapy and RT alone, respectively, before, during, and after treatment. Blood samples were cultured in RPMI-1640 complete medium containing 1% phytohemagglutinin and incubated in a CO2 incubator. Cytochalasin-B was added to the cultures at a final concentration of 5μg/ml. Finally, harvesting, slide making, and analysis were performed according to standard procedures. Results indicate that there was no significant difference between the frequencies of MN in lymphocytes of individuals before being treated with RT alone or chemo-radiotherapy. In the middle of treatment, (after 12 fractions of RT) the frequency of MN increased significantly compared with their concurrent pre-treatment samples in both groups (four-fold). However, the frequency of MN observed for RT patients was not significantly different with those received chemo- and radiotherapy. At the end of treatment, (after 24 fractions of radiotherapy) an increase in the MN frequency was observed for chemo-radiation group significantly higher than RT group (P=0.022). Mild increase in MN frequency in lymphocytes of patients receiving chemoradiation only after the completion of treatment course might be indicative of resistance induced by chemotherapeutics to the clastogenic effects of radiation. Therefore, using these agents repeatedly for cancer treatment in combination with radiation might not cause severe adverse biological effects in normal tissues.
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
Yang Z, Gu X, Zhao S, et al. Long term survival of radiotherapy for esophageal cancer: analysis of 1136 patients surviving for more than 5 years. Int J Radiat Oncol Biol Phys 1983;9(12):1769-73.
Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61(5):388-401.
Ohtsu A, Yoshida S. Chemotherapy and chemoradiotherapy for esophageal cancer. Crit Rev Oncol Hematol 1998;28(3):173-80.
Al-Sarraf M, Martz K, Herskovic M, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15(1):277-84.
Cooper S, Herskovic A, Macdonald JS, et al. Chemoradiotherapy of locally advanced esophageal cancer. JAMA 1999;281(17):1623-7.
Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002;38:300-13.
Sischy B, Smith T, Haller D. Interim report of EST 1282 phase III protocol for the evaluation of combined modalities in the treatment of patients with carcinoma of the esophagus. Proc Am Soc Clin Oncol 1990;9:105.
Herskovic A, Martz K, Al-Sarraf M, et al. combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New Engl J Med 1992;326(240:1593-8.
Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer J Clin Oncol 2007;25(26):4110-7.
S´ anchez-Su´ arez P, Ostrosky-Wegman P, Gallegos- Hern´ andez F, et al. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res 2008;640(1-2):8-15.
Joiner M, Kogel AV. Basic clinical Radiobiology. 4th ed. London: Hodder Irnold; 2009: p. 246-58.
Schaake-Koning C, Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall-cell lung cancer. New Engl J Med 1992;326(8):524-30.
Herscher LL, Cook JA, Pacelli R, et al. Principles of Chemoradiation: Theoretical and Practical Considerations. Oncology 1999;13(10 Suppl 5):11-22.
Stone HB, Coleman CN, Anscher M, et al. Effects of radiation on normal tissue:consequences and mechanisms. Lancet Oncol 2003;4(9):529-36.
Jianlin L, Jiliang H, Lifen J, et al. Measuring the genetic damage in cancer patients during radiotherapy with three genetic end-points. Mutagenesis 2004;19(6):457-64.
Kiltie AE, Ryan AJ, Swindell R, et al. A correlation between residual radiation-induced DNA double-strandbreaks in cultured ®broblasts and late radiotherapyreactions in breast cancer patients. Radiother Oncol 1999;51(1):55-65.
Mozdarani H, Jadidi M. The interaction of radiation and intercalating agents in normal bone marrow cells as evaluated by spleen colony assay technique: The effects of bleomycin sulfate and actinomycin D. MJIRI 1995;9(2):137-45.
Mozdarani H, Saberi AH. Induction of cytogenetic adaptive response of mouse bone marrow cells to radiationby therapeutic doses of bleomycin sulfate and actinomycin D as assayed by the micronucleus test. CancerLetters1994;78(1-3):141-50.
Yunis JJ. The chromosomal basis of human neoplasia. Science 1983;221(4607):227-36.
Bonassi S, Hagmar L, Strömberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 2000;60(6):1619-25.
Mozdarani H, Mansouri Z, Haeri A. Cytogenetic radiosensitivity of G0- lymphocytes of breast cancer and esophageal cancer patients as determined by micronucleus assay. J Radiat Res 2005;46(1):111-6.
Murty V, Mitra AB, Luthra UK. Spontaneous chromosomal aberrations inpatients with precancerous and cancerous lesions of the cervix uteri. Cancer Genet Cytogenet 1985;17(4):347-53.
Ochi h, Watanabe S, Furuya T, et al. Chromosome fragility of lymphocytes from breast cancer patients in relation to epidemiological data. Jpn J Cancer Res 1988;79(9):1024-30.
Venkatachalam P, Paul SFD, Mohankumar MN, et al. Frequency of dicentrics and micronuclei in peripheral blood lymphocytes of cancer patients. Mutat Res 1999;425(1):1-8.
Berg-de-Ruiter E, de Jong B, Mudler NH, et al. Chromosome damage in the peripheral blood lymphocytes of patients treated for testicular cancer. Hum Genet 1990;84(2):191-4.
Baciuchka-Palmaro MTO, Duffaud F, Sari-Minodier I, etal. Acentromeric micronuclei are increased in peripheral blood lymphocytes of untreated cancer patients. Mutat Res 2002;520(1-2):189-98.
Jagetia GC, Jayakrishnan A, Fernandes D, et al. Evaluation of micronuclei frequency in the cultured peripheral blood lymphocytes of cancer patients before and after radiation treatment. Mutat Res 2001;491(1-2):9-16.
Fenech M. The in vitro micronucleus technique. Mutat Res2000;455(1-2):81-95.
Wolff AH, Hennies H, Herrmann AMK, et al. Comparison of the Micronucleus and Chromosome AberrationTechniques for the Documentation of Cytogenetic Damage in Radiochemotherapy-Treated Patients with Rectal Cancer. Strahlenther Onkol 2011;187(1):52-8.
Iarmarcovai G, Ceppi M, Botta A, et al. Micronucleifrequency in peripheral blood lymphocytes of cancerpatients:A meta-analysis. Mutat Res 2008;659(3):274-83.
Rigaud O, Guedeney G, Duranton I, et al. Genotoxiceffects of radiotherapy and chemotherapy on thecirculating lymphocytes of breast cancer patients. I. Chromosome aberrations induced in vivo. Mutat Res 1990;242(1):17-23.
Banerjee B, Sharma S, Hegde S, et al. Analysis of telomere damage by fluorescence in situ hybridisation on micronuclei in lymphocytes of breast carcinoma patients after radiotherapy. Breast Cancer Res Treat2008;107(1):25-31.
Palyvoda O, Polañska J, Wygoda A, et al. DNA damageand repair in lymphocytes of normal individuals andcancer patients: studies by the comet assay andmicronucleus tests. Acta Biochimica Polonica 2003;50(1):181-90.
Distel L, Neubauer S, Keller U, et al. Individualdifferences in chromosomal aberrations after in vitroirradiation of cells from healthy individuals,cancer and cancer susceptibility syndrome patients. Radiotherapy and Oncology 2006;81(3):257-63.
Gamulin M, Garaj-Vrhovac V, Kopjar N. Evaluation ofDNA Damage in Radiotherapy-Treated Cancer Patients Using the Alkaline Comet Assay. Coll Antropol 2007;31(3):837-45.
Hille A, Hofman-H H, Ku ¨hnle E, et al. Spontaneous and radiation-induced chromosomal instability and persistence of chromosome aberrations after radiotherapy inlymphocytes from prostate cancer patients. Radiat Environ Biophys 2010;49(1):27-37.
Aristei C, Stracci F, Guerrieri P, et al. Frequency of sisterchromatid exchanges and micronuclei monitored over time in patients with early-stage breast cancer: results of anobservational study. Cancer Genet Cytogenet2009;192(1):24-9.
Shahidi M, Mozdarani H, Bryant PE. Radiation sensitivityof leukocytes from healthy individuals and breast cancer patients as measured by the alkaline and neutral cometassay. Cancer Letters 2007;257(2):263-73.
Richards RI. Fragile and unstable chromosome in cancer: causes and consequences. Trends Genet 2001;17(6):339-45.
Fenech M, Morley AA. The effect of donor age on the spontaneous and induced micronuclei. Mutat Res 1985;148(1-2):99-105.
Thierens H, Vral A, de Ridder L. Biological dosimetry using micronucleus assay for lymphocytes: interindividual differences in dose response. Health Phys 1991;62(5):623-30.
Rudd NL, Hoar DI, Martin RH, et al. Factors distinguishing couples at risk for non-disjunction. Can J Genet Cytol 1984;26(5):595-606.
Prosser JS, Moguet JE, Lloyd DC, et al. Radiation induction of micronuclei in human lymphocytes. Mutat Res 1988;199(1):37-45
Weichenthal M, Roser M, Ehlert U, F, et al. Increased numbers of spontaneous micronuclei in blood lymphocytes and cultured fibroblasts of individuals with familial cutaneous malignant melanoma. J Cancer Res Clin Oncol 1989;115(3):264-8.
| Files | ||
| Issue | Vol 54, No 1 (2016) | |
| Section | Original Articles | |
| Keywords | ||
| Esophageal cancer Lymphocytes Micronuclei Radiotherapy Chemotherapy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
